目的 探讨丹七软胶囊联合布洛芬治疗原发性痛经的临床疗效。方法 选取2020年1月—2021年6月张家港市中医医院收治的160例原发性痛经患者，按照随机数字表法分为对照组和治疗组，每组各80例。对照组口服布洛芬缓释胶囊，于经前3 d开始服药，0.3 g/次，2次/d。治疗组在对照组基础上口服丹七软胶囊，于经前3 d开始服药，5粒/次，3次/d。每个月经周期连服7 d，连续治疗3个月经周期。观察两组的临床疗效，比较治疗前后两组腹痛视觉模拟评分法（VAS）评分、痛经症状评分、36项健康调查简表（SF-36）总分，血流变参数[全血高、低切黏度（HBV、LBV），血浆黏度（PV），红细胞比容（HCT）]。统计两组不良反应情况。结果 治疗后，治疗组总有效率是95.00%，较对照组的85.00%显著提高（P＜0.05）。治疗后，两组腹痛VAS评分、痛经症状评分均显著降低，SF-36总分均显著升高（P＜0.05）；治疗后，治疗组腹痛VAS评分、痛经症状评分低于对照组，SF-36总分高于对照组（P＜0.05）。治疗后，两组HBV、LBV、PV、HCT均显著降低（P＜0.05）；以治疗组下降更显著（P＜0.05）。治疗后，治疗组和对照组不良反应发生率分别是5.00%、3.75%，两组不良反应发生率比较差异无统计学意义。结论 丹七软胶囊联合布洛芬治疗原发性痛经有确切疗效，能有效减轻患者痛经相关症状和疼痛程度，提高生活质量，改善机体血液流变性，且患者耐受性较好。

Objective To investigate the clinical efficacy of Danqi Soft Capsules combined with ibuprofen in treatment of primary dysmenorrhea. Methods A total of 160 patients with primary dysmenorrhea admitted to Zhangjiagang Hospital of Traditional Chinese Medicine from January 2020 to June 2021 were selected and divided into control group and treatment group according to random number table method, with 80 cases in each group. Patients in the control group were po administered with Ibuprofen Sustained-release Capsules 3 days before menstruation, 0.3 g/time, twice daily. Patients in the treatment group were po administered with Danqi Soft Capsules on the basis of the control group 3 days before menstruation, 5 grains/time, three times daily. Each menstrual cycle was treated for 7 d, and the treatment lasted for 3 consecutive menstrual cycles. The clinical effect of the two groups was observed, and the visual analogue scale (VAS) score, dysmorrhea symptom score, 36-item health Survey Short Form (SF-36) total score, hemorheological parameters [whole blood high and low shear viscosity (HBV, LBV), plasma viscosity (PV), erythrocyte specific volume (HCT)] were compared between the two groups before and after treatment. The adverse reactions of the two groups were analyzed. Results After treatment, the total effective rate in the treatment group was 95.00%, which was significantly higher than 85.00% in the control group (P < 0.05). After treatment, abdominal pain VAS score and dysmenorrhea symptom score were significantly decreased, and SF-36 total scores were significantly increased in both groups (P < 0.05). After treatment, the scores of abdominal pain VAS and dysmenorrhea symptoms in the treatment group were lower than those in the control group, while the total score of SF-36 in the treatment group was higher than that in the control group (P < 0.05). After treatment, HBV, LBV, PV, and HCT were significantly decreased in both groups (P < 0.05). The decrease was more significant in the treatment group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group and the control group was 5.00% and 3.75%, respectively, and there was no statistical significance in the incidence of adverse reactions between the two groups. Conclusion Danqi Soft Capsules combined with ibuprofen has definite curative effect in treatment of primary dysmenorrhea, and can effectively reduce dysmenorrhea related symptoms and pain degree, improve the quality of life and the body blood rheology with good tolerance.

R984